Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic …
…, KH Pflüger, S Schott, V Goede, S Isfort… - Journal of Clinical …, 2012 - ascopubs.org
Purpose We investigated the safety and efficacy of bendamustine and rituximab (BR) in
previously untreated patients with chronic lymphocytic leukemia (CLL). Patients and Methods In …
previously untreated patients with chronic lymphocytic leukemia (CLL). Patients and Methods In …
[HTML][HTML] Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
…, S Parmentier, F Lang, R Hansen, S Isfort… - Journal of hematology & …, 2016 - Springer
Background Patients with Ph-negative myeloproliferative neoplasms (MPN), such as
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at …
polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at …
[HTML][HTML] Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated …
…, C Schubert, J Köhler, M Schemionek, S Isfort… - Journal of hematology & …, 2016 - Springer
Background Somatic calreticulin (CALR), Janus kinase 2 (JAK2), and thrombopoietin receptor
(MPL) mutations essentially show mutual exclusion in myeloproliferative neoplasms (MPN…
(MPL) mutations essentially show mutual exclusion in myeloproliferative neoplasms (MPN…
Improve hip fracture outcome in the elderly patient (iHOPE): a study protocol for a pragmatic, multicentre randomised controlled trial to test the efficacy of spinal versus …
…, F Hildebrand, RD Hilgers, A Hoeft, S Isfort… - BMJ open, 2018 - bmjopen.bmj.com
Introduction Hip fracture surgery is associated with high in-hospital and 30-day mortality
rates and serious adverse patient outcomes. Evidence from randomised controlled trials …
rates and serious adverse patient outcomes. Evidence from randomised controlled trials …
Second cancers in MPN: Survival analysis from an international study
…, A Tieghi, V Recasens, S Isfort… - American journal of …, 2020 - Wiley Online Library
One out of ten patients with Philadelphia‐negative myeloproliferative neoplasms (MPN) develop
a second cancer (SC): in such patients we aimed at assessing the survival impact of SC …
a second cancer (SC): in such patients we aimed at assessing the survival impact of SC …
Comparison of flow‐FISH and MM–qPCR telomere length assessment techniques for the screening of telomeropathies
…, I Halfmeyer, N Estrada, B Xicoy, S Isfort… - Annals of the New …, 2020 - Wiley Online Library
Assessment of telomere length (TL) in peripheral blood leukocytes is part of the diagnostic
algorithm applied to patients with acquired bone marrow failure syndromes (BMFSs) and …
algorithm applied to patients with acquired bone marrow failure syndromes (BMFSs) and …
[HTML][HTML] Kidney dysfunction is associated with thrombosis and disease severity in myeloproliferative neoplasms: implications from the German Study Group for MPN …
…, M Bommer, HL Pahl, F Lang, M Kirschner, S Isfort… - Cancers, 2021 - mdpi.com
Simple Summary In patients with myeloproliferative neoplasms (MPN) and in patients with
kidney dysfunction, a higher rate of thrombosis has been reported compared with the general …
kidney dysfunction, a higher rate of thrombosis has been reported compared with the general …
[HTML][HTML] Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from …
…, M Tometten, A Abels, B Rolles, S Isfort… - International Journal of …, 2020 - mdpi.com
Dyskeratosis congenita (DKC) is a rare inherited disease of impaired telomere maintenance
that progressively leads to multi-organ failure, including the bone marrow. By enhancing …
that progressively leads to multi-organ failure, including the bone marrow. By enhancing …
[HTML][HTML] Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German …
P Cramer, S Isfort, J Bahlo, S Stilgenbauer… - …, 2015 - ncbi.nlm.nih.gov
To evaluate the effect of first-line and subsequent therapies, the outcome of 1,558 patients
with chronic lymphocytic leukemia from five prospective phase II/III trials conducted between …
with chronic lymphocytic leukemia from five prospective phase II/III trials conducted between …
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita
…, S Balabanov, B Rolles, S Isfort… - British journal of …, 2021 - Wiley Online Library
Dyskeratosis Congenita (DKC) is a systemic disorder caused by mutations resulting in impaired
telomere maintenance. Clinical features include bone marrow failure and an increased …
telomere maintenance. Clinical features include bone marrow failure and an increased …